|
Table of Contents
Director’s Message
Staff Profiles
Program Description
Program Information
Guidelines for Application
Preceptorships
Post-Fellowship Employment
Life Outside the NCI
|
2007 Application Catalog
Preceptorships - Division of Cancer Prevention
Organ Systems Research Groups
The Prostate and Urologic Cancer Research Group promotes and supports extramural basic and applied research that focuses on the prevention of prostate and urologic cancers. The Group plans, develops, implements, and monitors chemoprevention clinical trials that employ pharmacologic, biologic, genetic, immunologic, and vaccine interventions. The overall goal is to evaluate and validate new technologies that identify premalignant lesions and to develop novel chemopreventive agents to reduce cancer incidence.
Chief: Howard Parnes, M.D.
Potential Preceptor:
Ronald Lieberman, M.D.
Prostate and urological cancer research.
- Literature review, synthesis, and identification of research gaps in prostate and urologic cancer prevention.
- Surrogate endpoint biomarker identification and validation in prostate and urological prospective chemoprevention clinical trials.
- Clinical trial designs for evaluation of biochemical of biomarker endpoints.
- Development of risk models for prostate and urologic cancers.
- Design of phase I, II, III clinical trials to test novel chemoprevention agents.
- Identify independent research projects utilizing secondary data.
Joseph Tangrea, Ph.D.
A pharmacologist/epidemiologist whose main research interests are in the epidemiology and translational research of prostate and colorectal cancers.
- Explore the molecular epidemiology of prostate cancer, with emphasis on the development and testing of molecular markers for translation into clinical applications of early detection and prognosis prediction.
- Examine and evaluate candidate chemopreventive agents in the prevention of prostate cancer among men with prostatic intraepithelial neoplasia or the prevention of recurrence of prostate cancer in men with clinically localized disease.
- Examine relation of biochemical measures of vitamin D and genetic polymorphisms of vitamin D metabolism on the risk of prostate and colorectal cancer.
- Explore pharmaco-epidemiologic associations between various pharmaceuticals (e.g., NSAIDs, calcium channel blockers, antidepressants) and cancer risk.
- Examine risk factors and molecular markers associated with subsequent the risk of non-melanoma skin cancer and its precursors in the ISO-BCC study, a clinical trial investigating the efficacy of a low dose synthetic retinoid in the prevention of skin cancer.
|
